Advertisement

Drugs

, Volume 78, Issue 13, pp 1339–1352 | Cite as

Supervised Injectable Opioid Treatment for the Management of Opioid Dependence

  • James Bell
  • Vendula Belackova
  • Nicholas Lintzeris
Review Article
  • 75 Downloads

Abstract

Since the 1990s, there have been seven clinical trials, and considerable clinical experience, in supervised injectable opioid treatment (SIOT) for individuals who, despite previous treatments, continue to inject illicit heroin and experience harmful health and social consequences. Most studies prescribed pharmaceutical heroin (diacetyl morphine, or DAM). This paper critically reviews randomised trials, long-term follow-up studies and qualitative reports of SIOT, and briefly reviews evidence regarding other medications used in injectable treatment as an alternative to DAM. It seeks to identify critical, unresolved issues regarding this treatment. Randomised trials comparing DAM with oral methadone (OM) report that while in treatment, participants randomised to DAM used less street heroin; reported spending less money on drugs, committed fewer crimes, and experienced improved health. Similar findings pertain to SIOT with hydromorphone. Because of the risks of overdose, diversion, and misuse, all recent trials of injected DAM involved supervised administration. This contributes to treatment being expensive to deliver. There is conflicting evidence regarding societal cost effectiveness, with some studies estimating that the reduction in crime more than compensates for the expense of the treatment. The critical, unresolved issues concerning this modality of treatment relate to the way in which it is approached—either as a medium-term, intensive intervention where other treatment has failed, designed to bring people into conventional opioid agonist treatment (OAT); or an indefinite support aimed at reducing social and personal harm. The former seems in line with the available findings on long-term effectiveness of SIOT and might be more acceptable given its rather moderate cost.

Notes

Compliance with Ethical Standards

Funding

This work was completed without external funding.

Conflict of Interest

Dr. Bell is employed by Uniting MSIC to develop a clinical trial of SIOT. In the last 5 years he has received research support from Reckittbenckiser, served on an Advisory Board for Indivior, has received speaker fees and support to attend conferences from Indivior. Dr. Belackova is employed by Uniting MSIC in developing a trial of SIOT. Prof. Lintzeris has provided consultancies for Indivior and Mundipharma on unrelated projects.

References

  1. 1.
    United Nations Office on Drugs and Crime. World drug report. Vienna: United Nations; 2012.Google Scholar
  2. 2.
    United Nations Office on Drugs and Crime. World drug report. Vienna: United Nations; 2017.Google Scholar
  3. 3.
    Degenhardt L, Charlson F, Mathers B, Hall W, Flaxman A, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109:1320–33.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36(1):559–74.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Thomson E, Lampkin H, Maynard R, Karamouzian M, Jozaghi E. The lessons learned from the fentanyl overdose crises in British Columbia, Canada. Addiction. 2017;112(11):2068–70.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Hulse G, English D, Milne E, Holman C. The quantification of mortality resulting from the regular use of illicit opiates. Addiction. 1999;94:221–9.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction. 2002;97:1383–94.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Maxwell J, Pullum T, Tannert K. Deaths of clients in methadone treatment in Texas 1994–2002. Drug Alcohol Depend. 2005;78:73–81.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal. 2011;3(2):89–96.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    McLean S, Bruno R, Brandon S, de Graaff B. Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets. Harm Reduct J. 2009;6(1):37.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Passini S. The delinquency–drug relationship: the influence of social reputation and moral disengagement. Addict Behav. 2012;37(4):577–9.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Hall W. The contribution of research to Australian policy responses to heroin dependence 1990–2001: a personal retrospection. Addiction. 2004;99(5):560–9.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    McLellan A, McKay J, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction. 2005;100:447–58.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Gossop M, Marsh D, Stewart D, Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend. 2001;62(3):255–64.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years’ outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction. 2007;103:80–8.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009.  https://doi.org/10.1002/14651858.CD002209.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673–84.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Beynon CM, Bellis MA, McVeigh J. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the North West of England. BMC Public Health. 2006;6(1):205.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    De Maeyer J, Vanderplasschen W, Camfield L, Vanheule S, Sabbe B, Broekaert E. A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals. Int J Nurs Stud. 2011;48(10):1244–57.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1):151–7.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–88.CrossRefGoogle Scholar
  22. 22.
    Moffatt S, Weatherburn D, Donnelly N. What caused the recent drop in property crime? Crime Justice Bull. 2005;85:2.Google Scholar
  23. 23.
    Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009;35(1):28–33.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Bell J, Burrell T, Indig D, Gilmour S. Cycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002. Drug Alcohol Depend. 2006;81:55–61.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Van den Brink W, Hendriks VM, van Ree JM. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues. 1999;29(3):587–607.CrossRefGoogle Scholar
  26. 26.
    Public Health England. Drug misuse and dependence: UK guidelines on clinical management. Global and Public Health/Population Health/Healthy Behaviours; 2017.Google Scholar
  27. 27.
    Lintzeris N. Prescription of heroin for the management of heroin dependence. CNS Drugs. 2009;23(6):463–76.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Uchtenhagen A. Heroin maintenance treatment: from idea to research to practice. Drug Alcohol Rev. 2011;30:130–7.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, Van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, et al. Efficacy of heroin-assisted treatment in Belgium: a randomised controlled trial. Eur Addict Res. 2015;21(4):179–87.CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Blanken P, Hendriks VM, Van Ree JM, Van Den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300–8.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ. 1998;317(7150):13–8.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Br J Psychiatry. 2007;191(1):55–62.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–86.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet. 2010;375(9729):1885–95.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31:203–11.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, et al. Loss of treatment benefit when heroin-assisted treatment is stopped after 12 months. J Subst Abuse Treat. 2016;69:72–5.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Strang J, Groshkova T, Metrebian N. Recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. Luxembourg: Publications Office of the European Union; 2012.Google Scholar
  39. 39.
    Oviedo-Joekes E, Guh D, Brissette S, Marchand K, MacDonald S, Lock K, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):447–55.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    BCCS. Guidance for injectable opioid agonist treatment for opioid use disorder. Vancouver: British Columbia Centre on Substance Use, Ministry of Health; 2017.Google Scholar
  41. 41.
    Rook EJ. Pharmacokinetics and pharmacodynamics of diacetylmorphine in opioid dependent patients. Utrecht: Faculteit Geneeskunde, Universiteit Utrecht; 2003.Google Scholar
  42. 42.
    Bammer G, Van den Brink W, Gschwend P, Hendricks V, Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev. 2003;22(3):363–71.CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat. 2009;37(1):95–100.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5–14.CrossRefPubMedCentralGoogle Scholar
  45. 45.
    Naber D, Haasen C. The German Model project for heroin-assisted treatment of opioid dependent patients—a multi-site, randomised controlled treatment study Part 1. Hamburg: Centre for Interdisciplinary Addiction Research of Hamburg University; 2006.Google Scholar
  46. 46.
    Metrebian N, Groshkova T, Hellier J, Charles V, Martin A, Forzisi L, et al. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). Addiction. 2015;110(3):479–90.CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Güttinger F, Gschwend P, Schulte B, Rehm J, Uchtenhagen A. Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up. Eur Addict Res. 2003;9(2):73–9.CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Oviedo-Joekes E, March JC, Romero M, Perea-Millia E. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010;29(1):75–80.CrossRefPubMedCentralGoogle Scholar
  49. 49.
    Verthein U, Bonorden-Kleij K, Degkwitz P, Dilg C, Köhler WK, Passie T, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960–6.CrossRefPubMedCentralGoogle Scholar
  50. 50.
    Naber D, Haasen C. The German Model project for heroin-assisted treatment of opioid dependent patients—a multi-site, randomised controlled treatment study Part 2. Hamburg: Centre for Interdisciplinary Addiction Research of Hamburg University; 2006.Google Scholar
  51. 51.
    Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, et al. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment. Subst Abuse Treat Prev Policy. 2014;9(1):23.CrossRefPubMedCentralGoogle Scholar
  52. 52.
    Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005;330(7503):1297.CrossRefPubMedCentralGoogle Scholar
  53. 53.
    Byford S, Barrett B, Metrebian N, Groshkova T, Cary M, Charles V, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry. 2013;203(5):341–9.CrossRefPubMedCentralGoogle Scholar
  54. 54.
    Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Can Med Assoc J. 2012;184(6):E317–28.CrossRefGoogle Scholar
  55. 55.
    Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, et al. A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial. Addict Sci Clin Pract. 2014;9(1):21.CrossRefPubMedCentralGoogle Scholar
  56. 56.
    Boyd S, Murray D, MacPherson D. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14(1):27.CrossRefPubMedCentralGoogle Scholar
  57. 57.
    Boyd S. Yet they failed to do so: recommendations based on the experiences of NAOMI research survivors and a call for action. Harm Reduct J. 2013;10(1):6.CrossRefPubMedCentralGoogle Scholar
  58. 58.
    Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, et al. Heroin-assisted treatment in the Netherlands: history, findings, and international context. Eur Neuropsychopharmacol. 2010;20:S105–58.CrossRefPubMedCentralGoogle Scholar
  59. 59.
    Romo N, Poo M, Ballesta R. From illegal poison to legal medicine: a qualitative research in a heroin-prescription trial in Spain. Drug Alcohol Rev. 2009;28(2):186–95.CrossRefPubMedCentralGoogle Scholar
  60. 60.
    Demaret I, Litran G, Magoga C, Deblire C, Dupont A, De Roubaix J, et al. Why do heroin users refuse to participate in a heroin-assisted treatment trial? Heroin Addict Relat Clin Prob. 2014;41–48.Google Scholar
  61. 61.
    Zinberg NE. Drug, set, and setting: the basis for controlled intoxicant use. New Haven: Yale University Press; 1984.Google Scholar
  62. 62.
    Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253–63.CrossRefPubMedCentralGoogle Scholar
  63. 63.
    Bell J. Delivering effective methadone treatment. In: Ward J, Mattick RP, Hall W, editors. Methadone maintenance treatment and other opioid replacement therapies. Amsterdam: Harwood Academic Publishers; 1998.Google Scholar
  64. 64.
    Oviedo-Joekes E, Palis H, Marchand K, Guh D, MacDonald M, Harrison S, et al. Characteristics and response to treatment among Aboriginal people receiving treatment with injectable opioids for the treatment of long-term opioid-dependency. Int Perspect Subst Use Health Outcomes, Chicago; 2015.Google Scholar
  65. 65.
    Bell J, van der Waal R, Strang J. Supervised injectable heroin: a clinical perspective. Can J Psychiatry. 2016;62(7):451–6.CrossRefPubMedCentralGoogle Scholar
  66. 66.
    Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, et al. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study. J Subst Abuse Treat. 2010;38(4):408–11.CrossRefPubMedCentralGoogle Scholar
  67. 67.
    Stevens A. Weighting up crime: the overestimation of drug-related crime. Contemp Drug Probl. 2008;35(2/3):265.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • James Bell
    • 1
    • 2
  • Vendula Belackova
    • 2
  • Nicholas Lintzeris
    • 3
  1. 1.Kings College LondonLondonUK
  2. 2.Uniting MSICSydneyAustralia
  3. 3.University of SydneySydneyAustralia

Personalised recommendations